All News

Transcranial_magnetic_stimulation

Repetitive Transcranial Magnetic Stimulation in Fibromyalgia

d Jack Cush, MD

A randomized, sham-controlled trial has shown that repetitive transcranial magnetic stimulation (rTMS) reduced pain in fibromyalgia for up to 8 weeks; while analgesic effects waned, functional improvements remained during extended maintenance at week 16.

Read Article
falls.jpg (keep)

Cardiac-MSK Patients at Highest Risk for Falls and Death

d EurekAlert!

A new study by researchers at Peking University and the Chinese PLA General Hospital has found that multimorbidity—living with multiple chronic diseases—is closely associated with worsening fall conditions and mortality among middle-aged and older adults in China.

Read Article
morbidity,covid,heart,lung,brain

Predicting Premature Death with Multimorbidity

d Jack Cush, MD

Machine learning (ML) models were used to predict premature death in inflammatory bowel disease (IBD) patients with multimorbidity, the co-occurrence of 2 or more chronic conditions. 

Read Article
HLA-B%2A2705.png

Worse Outcomes in HLA-B27+ JIA

d MedPage Today

Patients with juvenile idiopathic arthritis (JIA) who carried the HLA-B27 genetic marker tended to have worse long-term outcomes, including lower rates of drug-free remission, in a prospective Scandinavian study.

Read Article
JAK Janus

Treating chronic inflammatory diseases with JAK inhibitors

d Science Daily

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.

Read Article
hip.fracture.jpg

Peripheral Nerve Blocks for Hip Fractures

d Jack Cush, MD

JAMA reviews the use of peripheral nerve block with hip fractures as an effective pain management strategy that can be performed by credentialed clinicians outside of the operating room.

Read Article
Korea National Health Insurance Database review shows that risk of mortality in Behcets patients is 28% higher than gen. population; highest in 1st 12 mos (OR 2.66). Major causes were CA, CVD, GI (viscus rupture), respiratory, & infections. Higher in younger pts. https://t.co/BoBmpF08bx
Dr. John Cush RheumNow ( View Tweet)
If COVID was responsible for causing autoimmune Dz (AD), it is possible that Molecular mimicry was in play. Study shows 10nsequence homology between SARS-CoV-2 & AD epitopes; 2) similar MHC binding; 3) of high empirical immunogenicity. https://t.co/n2KK0UZq1J https://t.co/HF7wyDlSBF

Links:

Dr. John Cush RheumNow ( View Tweet)
MD Anderson Cancer Center study of 1991 RA pts w/ prostate, lung or colon cancer showed TNFi use in 1st 3yrs did NOT affect survival. Use of TNFi vs csDMARDs - nonsign lowering in CRCA (HR 0·72;0·43–1·21), Lung CA (0·70;0·49–1·00), Prostate CA (0·80;0·44–1·44) https://t.co/6NsMYocdEl
Dr. John Cush RheumNow ( View Tweet)
Machine learning model can predict RA progression from seroneg (SN) undiff. arthritis. KURAMA cohort -210 SN pts -- 57 (27%) progressed to RA. FNN model best w/ AUC 0.924 & sensitivity 81%. Validated in ANSWER cohort (140 pts; 32% became RA) AUC 0.77 sensitivity 78%. MMP-3 had https://t.co/2kiAU8r3B8
Dr. John Cush RheumNow ( View Tweet)
Fresenius Receives FDA Approval for their Denosumab Biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) based on reference products: Prolia (denosumab) and Xgeva (denosumab) respectively. US launch mid-2025 https://t.co/sQMITpZbn3 https://t.co/up474pecNL

Links:

Dr. John Cush RheumNow ( View Tweet)
Treating chronic inflammatory diseases with JAK inhibitors Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since their approval, the https://t.co/MUHLUbK5Ml
Dr. John Cush RheumNow ( View Tweet)
Peripheral Nerve Blocks for Hip Fractures JAMA reviews the use of peripheral nerve block with hip fractures as an effective pain management strategy that can be performed by credentialed clinicians outside of the operating room. https://t.co/baeLWVxeUo https://t.co/ZBTVDT0jGR

Links:

Dr. John Cush RheumNow ( View Tweet)
A comprehensive examination of the pathogenesis and recent advancements in Familial Mediterranean Fever (FMF). This condition results from autosomal recessive mutations in the MEFV gene, which codes for Pyrin, a crucial component of the NLRP3 inflammasome. These genetic https://t.co/XNV89LW893
Dr. John Cush RheumNow ( View Tweet)
In 2021, the worldwide market for rheumatoid arthritis was valued at USD 22.77 billion and is projected to grow to USD 33.30 billion by 2030. https://t.co/HoUdQZfU8Q. https://t.co/Bcx9JMsavU

Links:

Dr. John Cush RheumNow ( View Tweet)
A study in mice shows that JAK inhibition In mice model of status epilepticus (SE) didnt prevent initial SE but when did effect chronic phase of Sz weeks after SE induction of SE, suppressing seizures, and epilepsy-associated histopathological alterations. Sz suppression lasted https://t.co/GMIPCtoc7x
Dr. John Cush RheumNow ( View Tweet)
ACPA specificity and recognition motifs examined in 6,907 patients with RA from 5 Scandinavian cohorts. ACPA targeting non-glycine citrulline motifs assoc. more strongly w/ HLA-SE; ACPA to glycine citrulline motifs assoc. w/ smoking and IgA ACPA A&R https://t.co/PmKv3dZLc4 https://t.co/NdPG4Orfj4

Links:

ACR_Journals ACR_Journals ( View Tweet)
Autoimmune Disease Impact Report Integrated Benefit Institute, a nonprofit independent research organization, has published its 2025 Autoimmune Disease Impact Report, which examines the health and productivity impacts of five prevalent and costly autoimmune conditions: https://t.co/TfXZti5NN3
Dr. John Cush RheumNow ( View Tweet)
Full read overview of Familial Mediterranean Fever pathogenesis & Advances. FMF is an autosomal recessive mutations of MEFV gene, encoding for Pyrin - fundamental element of the NLRP3 inflammasome. MEFV mutations lead to caspase-1 activation & IL-1b production https://t.co/AVm615HPXH
Dr. John Cush RheumNow ( View Tweet)
A study in mice shows that JAK inhibition In mice model of status epilepticus (SE) didnt prevent initial SE but when did effect chronic phase of Sz weeks after SE induction of SE, suppressing seizures, and epilepsy-associated histopathological alterations. Sz suppression lasted https://t.co/kvrAqc529V
Dr. John Cush RheumNow ( View Tweet)
×